Perceptions and Preferences of Indian Clinicians Towards Metoprolol–Am lodipine Fixed-Dose Combination Therapy in Hypertension Management: A Cross-Sectional Survey-Based Study
DOI:
https://doi.org/10.48165/ajm.2026.9.01.25Keywords:
Hypertension, Fixed-Dose Combination, Metoprolol, Amlodipine, Clinician Survey, Antihypertensive TherapyAbstract
Background:Hypertension remains a leading contributor to cardiovascular morbidity and mortality in India. Combination therapy using fixed-dose formulations like Metoprolol (a β-blocker) and Amlodipine (a calcium channel blocker) has gained attention for improved compliance and synergistic efficacy. However, clinician perspectives on such combinations remain underreported in Indian settings. Objective:To assess the perceptions, prescribing preferences, and clinical rationale of Indian medical professionals regarding the use of Metoprolol–Amlodipine fixed-dose combination (FDC) therapy in the management of hypertension.Methods:A descriptive, cross-sectional survey was conducted among 112 practicing clinicians using a structured questionnaire. The tool captured demographic details, prescribing patterns, therapeutic rationale, patient age-related choices, and perceived benefits or limitations of the Metoprolol–Amlodipine FDC.Results:The majority of respondents (78.6%) preferred the Metoprolol–Amlodipine combination over other antihypertensive FDCs, particularly in younger patients and those with coexisting anxiety or high sympathetic tone. Perceived advantages included effective BP control (86%), improved adherence (72%), and symptom relief. Logistic regression revealed significant associations between clinician age group, years of experience, and preference for the combination (p < 0.05).Conclusion:Indian clinicians show a strong preference for Metoprolol–Amlodipine FDC therapy, attributing it to enhanced therapeutic efficacy, tolerability, and patient compliance. These findings support the growing clinical utility of β-blocker–CCB combinations in routine hypertension management and underscore the need for updated guidelines reflecting real-world practices.
Downloads
References
Piepoli, M. F., Hoes, A. W., Agewall, S., et al. (2021). 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484
Castellano, J. M., Sanz, G., Peñalvo, J. L., et al. (2022). A polypill strategy to improve adherence: Results from the FOCUS study. Journal of the American College of Cardiology, 69(6), 628–639. https://doi.org/10.1016/j.jacc.2021.11.055
Petrella, R. J., Merikle, E., & Jones, J. (2021). Treatment inertia in patients with high cardiovascular risk: A real-world analysis. Cardiovascular Diabetology, 20(1), 46. https://doi.org/10.1186/s12933-021-01203-0
Franz, R. M., Braun, S., & Metzner, A. (2022). Clinical use of beta-blockers in elderly patients with coronary artery disease. Drugs & Aging, 39(2), 91–100. https://doi.org/10.1007/s40266-021-00908-7
Kumar, A., Sharma, M., & Jindal, N. (2023). Comparative efficacy of nebivolol vs other beta-blockers in CAD: A clinical review. American Journal of Cardiovascular Drugs, 23(1), 11–21. https://doi.org/10.1007/s40256-022-00529-8
Gupta, M., Singh, N., & Gupta, R. (2022). Role of combination therapy in hypertension: Amlodipine plus beta-blockers. Journal of the Association of Physicians of India, 70(5), 42–46. https://doi.org/10.59556/japi.70.0072
Jamerson, K., Weber, M. A., Bakris, G. L., et al. (2021). Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine, 359(23), 2417–2428. https://doi.org/10.1056/NEJMoa0806182
Zhang, W., Liu, Y., Sun, H., et al. (2023). Telmisartan attenuates endothelial dysfunction and oxidative stress via PPAR-γ activation in high-fat diet rats. Scientific Reports, 13(1), 10341. https://doi.org/10.1038/s41598-023-37549-y
Mobini, M., Aghaei, N., Gholami, M., et al. (2023). Medication adherence and its related factors in patients with cardiovascular disease: A cross-sectional study. BMC Cardiovascular Disorders, 23(1), 145. https://doi.org/10.1186/s12872-023-03191-4
Komiyama, Y., & Tanabe, K. (2022). The COMPELL study: Cilnidipine vs amlodipine for pedal edema in hypertension. Clinical and Experimental Hypertension, 44(6), 578–584. https://doi.org/10.1080/10641963.2022.2050232
PREVENT Collaborative Group. (2021). Effects of cilnidipine vs amlodipine on pedal edema in hypertensive patients. Journal of Clinical Hypertension, 23(1), 17–24. https://doi.org/10.1111/jch.14097
Mahajan, H., Kazi, Y., & Sharma, B. (2023). Cardiovascular risk factors among urban slum dwellers: A cross-sectional study. International Journal of Health Policy and Management, 12(1), 1053–1059. https://doi.org/10.34172/ijhpm.2023.106
Yusuf, S., Hawken, S., Ounpuu, S., et al. (2022). INTERHEART study: Modifiable risk factors for myocardial infarction across 52 countries. The Lancet, 364(9438), 937–952. https://doi.org/10.1016/S0140-6736(04)17018-9
Arnett, D. K., Blumenthal, R. S., Albert, M. A., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary. Journal of the American College of Cardiology, 74(10), 1376–1414. https://doi.org/10.1016/j.jacc.2019.03.009
Bansilal, S., Castellano, J. M., & Fuster, V. (2015). Global burden of cardiovascular disease: Focus on secondary prevention of cardiovascular disease. International Journal of Cardiology, 201(Suppl. 1), S1–S7. https://doi.org/10.1016/S0167-5273(15)31026-3
Sahoo, S., Sethy, G., Sahoo, S. K., et al. (2023). Efficacy and safety of fixed-dose combination of metoprolol and amlodipine in Indian patients with hypertension and CAD: A real-world evidence study. Indian Heart Journal, 75(4), 327–334. https://doi.org/10.1016/j.ihj.2023.07.002
Mahajan, K., Negi, P. C., Merwaha, R., et al. (2022). Burden of coronary artery disease and its risk factors in Himachal Pradesh: Results from a population-based study. Indian Heart Journal, 74(5), 431–438. https://doi.org/10.1016/j.ihj.2022.08.004
Zhao, D., Liu, J., Wang, M., Zhang, X., & Zhou, M. (2019). Epidemiology of cardiovascular disease in China: Current features and implications. Nature Reviews Cardiology, 16(4), 203–212. https://doi.org/10.1038/s41569-018-0119-4
Krittanawong, C., Virk, H. U. H., Kumar, A., et al. (2022). Trends in adherence to secondary prevention guidelines for coronary artery disease among US adults: NHANES 2001–2016. European Journal of Preventive Cardiology, 29(9), 1389–1398. https://doi.org/10.1093/eurjpc/zwab175
Gupta, R., Joshi, P., Mohan, V., Reddy, K. S., & Yusuf, S. (2008). Epidemiology and causation of coronary heart disease and stroke in India. Heart, 94(1), 16–26. https://doi.org/10.1136/hrt.2007.132951
